This content is machine translated Melanocytic tumors The latest developments in the field of immunotherapy The market approval of checkpoint inhibitors has sustainably improved the options for melanoma treatment. Impressive survival rates have been achieved in long-term studies. Although there are still many open questions,…
View Post 1 min This content is machine translated Squamous cell carcinoma Pembrolizumab as first-line therapy reduces mortality rate In a phase III trial, pembrolizumab improved overall survival in patients with recurrent or metastatic head and neck squamous cell carcinoma.
